Tyrosine Sulfation at Antibody Light Chain CDR-1 Increases Binding Affinity and Neutralization Potency to Interleukine-4
-
Published:2024-02-05
Issue:3
Volume:25
Page:1931
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
D’Antona Aaron M.1, Lee Julie M.2, Zhang Melvin3, Friedman Clarence1, He Tao1, Mosyak Lidia1, Bennett Eric1, Lin Laura1, Silverman Maddison1, Cometa Funi1, Meade Caryl1, Hageman Tyler1ORCID, Sousa Eric1, Cohen Justin1, Marquette Kimberly1, Ferguson Darren1, Zhong Xiaotian1
Affiliation:
1. BioMedicine Design, Pfizer Research & Development, 610 Main Street, Cambridge, MA 02139, USA 2. Translational Clinical Sciences, Pfizer Discovery & Early Development, 610 Main Street, Cambridge, MA 02139, USA 3. Inflammation and Immunology Research Unit, Pfizer Research & Development, 610 Main Street, Cambridge, MA 02139, USA
Abstract
Structure and function of therapeutic antibodies can be modulated by a variety of post-translational modifications (PTM). Tyrosine (Tyr) sulfation is a type of negatively charged PTM that occurs during protein trafficking through the Golgi. In this study, we discovered that an anti-interleukin (IL)-4 human IgG1, produced by transiently transfected HEK293 cells, contained a fraction of unusual negatively charged species. Interestingly, the isolated acidic species exhibited a two-fold higher affinity to IL-4 and a nearly four-fold higher potency compared to the main species. Mass spectrometry (MS) showed the isolated acidic species possessed an +80-Dalton from the expected mass, suggesting an occurrence of Tyr sulfation. Consistent with this hypothesis, we show the ability to control the acidic species during transient expression with the addition of Tyr sulfation inhibitor sodium chlorate or, conversely, enriched the acidic species from 30% to 92% of the total antibody protein when the IL-4 IgG was co-transfected with tyrosylprotein sulfotransferase genes. Further MS and mutagenesis analysis identified a Tyr residue at the light chain complementarity-determining region-1 (CDRL-1), which was sulfated specifically. These results together have demonstrated for the first time that Tyr sulfation at CDRL-1 could modulate antibody binding affinity and potency to a human immune cytokine.
Reference70 articles.
1. Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2017). Essentials of Glycobiology, Cold Spring Harbor Laboratory Press. [3rd ed.]. 2. Vertebrate protein glycosylation: Diversity, synthesis and function;Moremen;Nat. Rev. Mol. Cell Biol.,2012 3. Zhong, X., and Wright, J.F. (2013). Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications. Int. J. Cell Biol., 2013. 4. Posttranslational Modifications and the Immunogenicity of Biotherapeutics;Jefferis;J. Immunol. Res.,2016 5. Global view of human protein glycosylation pathways and functions;Schjoldager;Nat. Rev. Mol. Cell Biol.,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|